Objective-Patients with bicuspid aortic valve (BAV) have an increased risk of developing ascending aortic aneurysms.
A thoracic aortic aneurysm (TAA) is the progressive enlargement of the thoracic aorta because of destructive changes in the connective tissue of the media and adventitia in the aortic wall, a condition that may lead to aortic dissection or rupture. Individuals with a bicuspid aortic valve (BAV) have a greater risk of developing aortic valve complications, ascending aortic aneurysms, and dissection, increasing the likelihood of the need for surgical interventions in the aortic valve and the aorta.
BAV is the most common congenital heart defect, the prevalence of which is between 0.5% and 2%; 1 men are predominantly affected by ≈2:1. The incidence of aortic dilatation in patients with BAV without significant valve dysfunction has been estimated to be as high as 50% to 70%. 2 Therefore, the burden of diseases that are associated with BAV is more significant than any other congenital cardiac defect. 3 Two major hypotheses have been proposed to explain the increased prevalence of ascending aortic dilatation, rupture, and dissection in patients with BAV. 4 The first hypothesis claims that a genetic or developmental abnormality in patients with BAV decreases aortic wall strength and predisposes it to complications. 5 In the second theory, greater blood velocity and eccentric flow jets that are caused by a BAV raise the shear stress on the ascending aortic wall and increase the risk of ascending aortic dilatation, dissection, and rupture. 6 Transforming growth factor-β (TGFβ) is a crucial factor that mediates vascular remodeling, and impaired signaling of this pathway can alter the structure and composition of the extracellular matrix. Notably, in some monogenic syndromes that are associated with TAAs (Marfan and Loeys-Dietz syndromes), TGFβ signaling is enhanced because of mutations in TGFβ pathway genes. 7 TGFβ1 is secreted and stored as a biologically inactive form in the extracellular matrix in the large latent TGFβ1 complex, which contains a TGFβ1 homodimer, latency-associated peptide (LAP), and latent TGFβ1-binding proteins (LTBPs). Alternatively, TGFβ1 is bound in the small latent complex, which comprises a TGFβ1 homodimer and LAP. Release of the large latent complex from the extracellular matrix (catalyzed by metalloproteinases) and dissociation of TGFβ1 from LAP are required for its activation and biological activity. The pathophysiological mechanisms of BAV-associated aortopathy are unknown, but TGFβ signaling has been implicated in BAV pathology. 8, 9 Previous studies have suggested that the development of aneurysm in BAV patients is characterized by lower TGFβ activity compared with tricuspid aortic valve (TAV) patients, distinguishing BAV-associated aneurysms from monogenic TAAs, based on data that fibrosis, which is stimulated by TGFβ, 10 increases during the development of aneurysms in TAV but not BAV patients. 11, 12 Moreover, inclusion of the extra domain A exon in the fibronectin gene, which is upregulated by TGFβ, is more frequent during the development of aneurysms in TAV versus BAV patients. 13 Because the lack of fibrosis and the differential splicing of fibronectin could be attributed to disparate TGFβ responses between BAV and TAV patients, we examined TGFβ signaling in aortic smooth muscle cells (AoSMCs) from BAV and TAV patients. To identify such differences in TGFβ responsiveness, gene expression profiles were constructed after TGFβ treatment of AoSMCs and valvular fibroblasts from patients with BAV and TAV. The resulting genes were then analyzed in expression profiles of vascular tissues in these patients. 14 Our findings suggest that there is no inherent difference between BAV and TAV with respect to TGFβ signaling; instead, the bioavailability and effects of active TGFβ are muted in patients with BAV.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Gene Expression Is Altered by TGFβ in Cultured AoSMCs From BAV Patients
Before any comparisons between the BAV and TAV cells we assessed whether the status of the aorta (aneurysmal or nonaneurysmal), from which primary cells were obtained, could affect the global gene expression profile in the SMCs. By principal component analysis, performed using all the expressed genes, we could not discriminate the expression pattern from SMCs deriving from a nondilated or dilated aortas ( Figure I in the online-only Data Supplement), a finding that allows us to consider the 7 BAV and 5 TAV patients in 2 groups, only discriminated by the cuspidity, without further subgrouping.
Comparing gene expression in BAV and TAV patients by paired t test for treated/untreated AoSMCs, with a P value adjustment to 5% false discovery rate, 217 genes were differentially expressed after TGFβ1 treatment of BAV AoSMCs, whereas no genes differed significantly between treated and untreated AoSMCs in TAV patients after correction for multiple testing ( Figure 1A and Table III in the online-only Data Supplement).
To determine whether the BAV-specific response to TGFβ was genetic and could be observed in other cell types, we analyzed the expression of the 217 responsive genes in fibroblasts from the aortic valves of BAV and TAV patients. As shown in Figure 1B , the expression of nearly all genes modulated significantly between control and treatment in BAV and TAV valvular fibroblasts. This observation indicates that the differential response of BAV patients to TGFβ is aorta-specific and is not conserved in other cell types. Gene ontology analysis revealed that the 217 genes were enriched in genes involved in pathways important for wound healing response, such as cell migration, angiogenesis, and focal adhesion (Table IV in 
TGFβ-Induced Genes in Cultured SMCs Are Differentially Expressed in the Intima-Media of BAV and TAV Patients With Ascending Aortic Aneurysm
To determine the relevance of the in vitro AoSMCs culture system to the in vivo media layer in patients, we analyzed the 217 differentially expressed genes identified using the ASAP database.
14 This database contains the information on gene expression arrays in the intima/media region of ascending aortas from 90 BAV and 49 TAV patients. The unique setup of the ASAP study, including aneurysmal and nonaneurysmal ascending aorta from BAV and TAV patients, allowed us to investigate the changes associated with the development of thoracic aneurysm in both valve types.
By principal component analysis analysis, there was a separation between the intima/media in BAV and TAV patients in dilated, but not in nondilated, aortas ( Figure 2 ). In other tissue biopsies from the same patient groups, that is the adventitia layer of the aorta, intima-media of mammary artery, and heart (133, 89, and 127 arrays respectively), the patients did not cluster into discrete groups, confirming that the effect is specific to the aorta ( Figure II in the online-only Data Supplement). Therefore, the in vivo separation of 217 genes in dilated BAV and TAV supports our in vitro system, strengthening the hypothesis that a disparate response to TGFβ1 distinguishes the development of aneurysms in BAV and TAV patients.
Using genes significantly modulated by TGFβ1 treatment in fibroblasts, we obtained a separation between BAV and TAV dilated aortas similar to the principal component analysis based on the 217 genes identified in TGFβ1-treated AoSMCs ( Figure III in the online-only Data Supplement).
As shown in the volcano plot in Figure 3 , the cluster effect between BAV and TAV dilated aortas, based on the 217 genes, is driven by changes that occur predominantly in TAV patients, where there are more significantly overexpressed genes (Table V in the online-only Data Supplement). Hence, TGFβ activation (both up-and downregulation) of the 217 genes during the formation of aneurysm occurs only in TAV patients.
Increased TGFβ Activity During TAA Formation in Patients With TAV but Not BAV
To analyze these results, we measured active TGFβ levels in the aortas of BAV and TAV patients. To measure TGFβ activity, we first performed immunohistochemistry to detect phosphorylated SMADs, the major transcription factors that are activated by the TGFβ cascade. Phosphorylated SMAD2 to 3 and SMAD1-5 to 8 staining was assessed in 48 patients (12 BAV and 12 TAV nondilated aortas, 12 BAV and 12 TAV dilated aortas). As shown in Figure 4 , there was intense staining of pSMAD2-3 and pSMAD1-5 to 8 during TAA formation in TAV patients, reflecting greater TGFβ activity during aneurysm formation in TAV compared with that in BAV patients. Next, we measured the amount of bioavailable TGFβ1. Using the bioassay that was developed by Khan et al, 15 it is possible to measure the actual amount of bioactive TGFβ. The principle behind the method exploits the luciferase emission in response to the activation of PAI-1 promoter. PAI-1 is the first gene whose transcription is induced by TGFβ signaling, 16, 17 thus the luciferase emitted by the mink lung epithelial cells is an indirect measurement of PAI-1 transcription activation by the free TGFβ. The TGFβ bioassay was performed on 8 aortas from 4 BAV and 4 TAV aneurysmal patients. As shown in Figure 5 , the amount of luciferase activity was significantly higher in TAV aneurysmal aorta lysates.
Decreased TGFβ Activity During Aneurysm Development in BAV Patients Is Determined by an Increased Sequestration in the Extracellular Matrix
We next wanted to understand the reasons behind the decreased TGFβ activity associated with aneurysm development in BAV patients. One hypothesis could be a general downregulation of genes in TGFβ signaling. To examine this, we compared the expression profiles of BAV and TAV aorta for genes in the TGFβ transduction cascade.
In nondilated aortas, TGFBR1 expression was significantly higher in BAV than in TAV ( Figure IVA in the online-only Data Supplement). Consistent with the gene expression data, TGFΒR1 protein levels were greater in nondilated aortas of BAV patients by immunohistochemistry versus those of TAV patients ( Figure IVC in the online-only Data Supplement). Moreover, the expression of SMAD7, an inhibitory SMAD protein, 18 was lower in BAV than in TAV ( Figure IVB in the online-only Data Supplement). Therefore, the lower TGFβ activity in BAV was not attributed to the downregulation of genes in TGFβ signaling; it more likely depends on (1) decreased TGFβ synthesis or (2) decreased bioavailability because of a greater binding of TGFβ to the extracellular matrix. Consequently, we measured mRNA levels of TGFβ1 and latent associated-binding proteins (LTBP1, LTBP2, LTBP3, and LTBP4). TGFβ1 expression was increased in BAV and TAV dilated patients compared with nondilated aortas, suggesting that the decreased TGFβ activity in BAV aneurysmal tissue is not attributed to TGFβ deficiency ( Figure  V in the online-only Data Supplement). Furthermore, LTBP2, LTBP3, and LTBP4 levels were higher during aneurysm formation in BAV aortas than in TAV (Figure V in the onlineonly Data Supplement), suggesting that TGFβ is sequestered in the matrix to a larger extent in BAV than in TAV. To test the possibility of increased TGFβ sequestration in the LTBP complex, we used double immunofluorescent staining to colocalize the amount of TGFβ (in its precursor form, LAP) with one of the LTBPs (LTBP3) that differentially changed in mRNA expression during aneurysm development, between BAV and TAV. The LTPB3-LAP colocalization was analyzed in 7 BAV and 7 TAV aneurysmal aortas by determining the Manders coefficient M2 which estimates the contribution of the red channel (labeling LAP) to the colocalized area (the yellow area resulting from the merge of red and green channels). 19 As presented in Figure 6 , in BAV dilated aortas, we detected a higher amount of LAP in complex with LTBP3, compared with the TAV aortas.
Altogether these observations could explain the decreased bioactive TGFβ levels in BAV aortic lysate by mink lung epithelial cells bioassay; because BAV aortic lysates contain a higher proportion of bound TGFβ compared with TAV, less free TGFβ is available to activate PAI-1 in the assay.
Discussion
In this study, we report that the development of aneurysms in patients with BAV is not associated with an increased TGFβ activity differentiating them from monogenic forms of TAAs (Marfan and Loeys-Dietz syndromes).
TGFβ remains the most frequently studied pathway in TAA, based on the extensive research on Marfan and Loeys-Dietz syndromes, in which a causative link between defective TGFβ signaling and TAA development has been identified. 7, [20] [21] [22] BAV-associated aneurysm/aortopathy is also thought to have a genetic cause, in which a developmental abnormality in patients with BAV decreases aortic wall strength and predisposes it to complications. 5 In addition, considering the central functions of TGFβ in heart valve formation, 23 defects in this pathway explain the congenital valve defect and increased risk of aneurysm formation in adults.
To extrapolate the existing data on the monogenic forms of TAA, such as Marfan and Loeys-Dietz syndrome, to the less well-characterized cause of BAV, it could be hypothesized that a change in TGFβ signaling also contributes to BAV-associated aortopathy. For instance, in Marfan syndrome, the most common hereditary disorder that is associated with aortic aneurysms, a mutation in FBN1 24 affects improper sequestration and higher bioavailability of TGFβ in the extracellular matrix. 20, 22 Loeys-Dietz syndrome is caused by missense mutations in TGFBR1 and TGFBR2, 21 also resulting in greater TGFβ signaling, elevated TGFβ activity during aneurysm formation causes the destruction of the aortic wall but in parallel to simultaneous activation of compensatory wound healing responses. 25 Accordingly, studies have shown that aneurysm, irrespective of cause, involves phosphorylation of SMADs. 8, 26 In these studies, aneurysmal tissues were compared with aortas of healthy transplant donors (likely to be individuals with a TAV). In our study, we examined aneurysmal and nonaneurysmal aortic biopsies of patients being accepted for surgery of aortic valve and ascending aorta. The availability of aneurysmal and nonaneurysmal tissue offered the possibility to specifically look into molecular changes that lead to the aortic dilatation event and finally compare the process with respect to the valve type. However, from the present work, we could not exclude an increased TGFβ activity in nondilated TAV and BAV aortas compared with the aorta of healthy organ donors.
We previously reported that a specific splice variant of fibronectin-extra domain A, known to be involved in wound healing and regulated by TGFβ, 27 was not upregulated in aneurysmal BAV aorta, underscoring the differences between BAV and monogenic forms of TAA. 13 Interestingly, it was recently shown that fibronectin-extra domain A is induced by disturbed hemodynamics and exerts a protective mechanism against hemorrhagic rupture of the intima. 28 The lack of TGFβ activation during aneurysm formation in BAV patients could result into impaired wound healing responses 11, 29 and be one of the causes for the increased susceptibility of BAV aortas to dissection. 28 One aim of this study was to determine whether the response of SMCs from BAV and TAV aortic biopsies to high concentrations of TGFβ was relevant to the molecular mechanisms of aneurysm development in these patients. A flow chart outlining the design of the study is presented in Figure VI in the online-only Data Supplement. We identified 217 differentially expressed genes in cells from BAV patients. Notably, no genes were significantly altered between treated and untreated AoSMCs in TAV patients after correction for multiple testing, suggesting lower responsiveness of TAV cells to TGFβ. One explanation for this observation is the difference in cell composition between biopsies of BAV and TAV aortas. We recently reported the absence of detectable fibrosis in BAV aortas, indicating that repair mechanisms are not activated in BAV, 11 implying the presence of fewer fibrosis-inducing myofibroblasts. 30 Therefore, it is likely that cells from TAV aortas contain primarily myofibroblast populations, which are less responsive to TGFβ. The myofibroblast phenotype does not change with transcriptional induction of extracellular matrix genes after treatment with TGFβ, 31 and the sensitivity to exogenous TGFβ declines during transdifferentiation into myofibroblasts. 32 Collectively, these findings suggest that once myofibroblasts have differentiated, their ability to respond to TGFβ wanes, preventing further induction of a new response.
We also examined the 217 TGFβ-responsive genes in fibroblasts from BAV and TAV aortic valves. All genes were differentially expressed in the cells from both valve types, implying that the response to TGFβ is not restricted to BAV AoSMCs. Moreover, this result confirmed that these genes reflect changes in expression in response to TGFβ. In line with this, gene ontology analysis revealed that the 217 genes were enriched in genes involved in pathways important for wound healing response such as cell migration, angiogenesis and focal adhesion (Table IV in the online-only Data Supplement).
By principal component analysis analysis of these 217 genes using the ASAP expression database, 14 we noted a separation between BAV and TAV patients only in dilated aortas, suggesting increased activity of TGFβ during aneurysm development. Indeed, our in vitro cell system was valuable in identifying TGFβ-responsive genes, which can be used to study the molecular aspects of aneurysm formation in vivo. Furthermore, activation (both up-and downregulation) of the 217 genes by TGFβ during aneurysm formation occurs only in TAV patients.
The lack of TGFβ activation during aneurysm formation in BAV patients could be a result of an increase in its sequestration in the extracellular space, an event that would lower the bioavailability and activity of TGFβ. Although active TGFβ must be measured to assess TGFβ-induced activity, this task is problematic because of the existence of TGFβ in various complexes, for example, in the extracellular matrix, associated with LAP, or covalently bound to LTBPs and other extracellular matrix proteins. Using mink lung epithelial cells that have been transfected with PAI-1 promoter-driven luciferase, we found that the amount of free/active TGFβ declined in BAV aneurysmal aortas versus TAV. The preferential upregulation of LTBP genes in BAV patients during aneurysm formation suggested that more TGFβ could be sequestrated in the matrix in BAV than in TAV. The link between less active TGFβ and increased binding in the LTBP complex in BAV patients was confirmed by colocalization analysis of LTBP3 and LAP using confocal microscopy. We found an increased colocalization of LAP and LTBP3 in aneurysmal aortas from BAV patients compared with aneurysmal aortas from TAV patients, a result that would differentiate BAV-associated TAA from Marfan-associated TAA.
To examine defective TGFβ signaling in BAV, we analyzed genes involved in the TGFβ pathway, such as receptors and intracellular proteins (eg, SMADs). We analyzed the aortic biopsies of nondilated patients to identify defects and impairments in TGFβ signaling before dilatation that might have potentiated the development of aneurysm in BAV. TGFBR1 was significantly upregulated in nondilated aortas in BAV patients compared with that in TAV, possibly because of a compensatory mechanism that was activated before dilation to overcome the increase in TGFβ sequestration in the extracellular matrix through formation of a complex with LTBPs. Notably, when we compared TGFβ-related genes between aneurysmal BAV and TAV aortas, endoglin was significantly upregulated in TAV (data not shown). Endoglin is a TGFβ coreceptor that regulates angiogenesis and promotes fibrosis, 33 suggesting that TGFβ activation during aneurysm development in TAV has a signature, correlating with wound healing mechanisms.
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Figure 6. Detection of latent TGFβ-binding proteins (LTBP)3 latency-associated peptide (LAP) colocalization in the intima-media area of dilated aortas of bicuspid aortic valve (BAV; top) and tricuspid aortic valve (TAV; bottom) patients. Double immunofluorescence labeling for LTBP3 (in green; Alexa-488-tagged) and LAP (in red; Alexa-594-tagged). Nuclei were stained with 4′,6-diamidino-2-phenylindole (in blue). The amount of colocalization was measured by using Image Pro Premier software, on 7 BAV and 7 TAV patients, and shown in the box-plot. *P value <0.05. L indicates lumen.
There are many limitations that need to be considered when interpreting the results. First, the biopsies were obtained from an elective surgical cohort, including both men and women in the age range of 29 to 82 years. However, there was no difference in age between BAV and TAV patients with a dilated aorta (BAV 61±10 versus TAV 63±13), in which we saw a difference in TGFβ activity. In addition, correlation analysis of sex-adjusted and unadjusted gene expression showed high correlation, justifying the use of unadjusted values. Second, the different morphotypes of the bicuspid valve were not taken into consideration in the present study. There is an ongoing debate whether the different cusp fusions could either reflect different genetic backgrounds or be associated with different flow patterns influencing the vascular remodeling. To perform stratified for morphotypes analyses a substantially larger cohort will be needed. An additional limitation of the gene expression analyses in vascular tissue is the mixed cell population which prevented cell-specific analyses. Although the major contribution to the expression profile is given by the media layer, we are aware of the more and more emerging importance of the endothelium in the aneurysm development process.
In conclusion, using transcriptomics, analyses of pSMADs levels and a measurement of bioavailable TGFβ combined with colocalization of TGFβ-precursor and LTBP3, we show that the development of TAA in BAV patients is not associated with an increased TGFβ signaling thus differentiating BAVassociated aortopathy from monogenic forms of TAAs, such as Marfan and Loeys-Dietz syndromes.
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